Evaluation of Marginal Bone Loss and Associated Factors Around Ziacom Dental Implants With Different Prosthetic Connection

Launched by UNIVERSIDAD DE GRANADA · May 11, 2023

Keywords

ClinConnect Summary

This clinical trial is examining how dental implants can experience bone loss over time, particularly focusing on the area around the upper part of the implant where it connects to the tooth restoration. Researchers want to understand the differences in bone loss between two types of dental implants: those with a conical connection and those with an internal hexagonal connection. They believe that implants with the hexagonal connection might lead to more bone loss due to higher levels of harmful bacteria and inflammation in the area around the implant.

To be eligible for this study, participants must have one missing tooth in the back of their mouth (either a premolar or molar) and have both neighboring teeth present. However, certain health conditions, such as uncontrolled diabetes, autoimmune diseases, or severe infections, may exclude someone from participating. If you join the study, you’ll be closely monitored over time for changes in bone levels and signs of inflammation or bacterial infection. This research aims to improve how dental implants are used and help prevent bone loss, ultimately leading to better dental health outcomes for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • One missing tooth in the premolar or molar area with both opposing and adjacent teeth (mesial and distal).
• Exclusion Criteria:
• • One-stage bone augmentation.
• • Uncontrolled type 1 or 2 diabetes (HgA1c\>8).
• • Known auto-immune or inflammatory disease.
• • Severe hematologic disorders, such as hemophilia or leukemia.
• • Local or systemic infection that may compromise normal healing (e.g., extensive periapical pathology).
• • Liver or kidney dysfunction/failure.
• • Currently receiving cancer treatment or within 18 months from completion of radio- or chemotherapy.
• • Long-term history of oral bisphosphonates use (i.e., 10 years or more).
• • History of intravenous bisphosphonates.
• • Long-term (\>3 months) history of antibiotics or drugs known to alter the inflammation and/or immunological system 3 months before inclusion.
• • Severe osseous diseases (e.g., Paget disease of bone).
• • Pregnant women or nursing mothers.
• • Not able or not willing to follow instructions related to the study procedures.